Smallpox eradication in Bangladesh, 1972-1976.

Vaccine

Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.

Published: December 2011

Rahima Banu, the world's last endemic case of severe smallpox, Variola Major, developed rash on October 16, 1975 on Bhola Island, Bangladesh. Achieving eradication in a country destroyed by war challenged the achievement of smallpox eradication. Between January 1, 1972 and December 31, 1975, 225,000 smallpox cases and 45,000 smallpox deaths occurred. Adapting the global smallpox eradication strategies of surveillance, the detection of smallpox cases, and containment, the interruption of smallpox transmission, utilized progress toward three objectives to monitor performance: (1) surveillance - the percent of smallpox infected villages detected within 14 days of the first case of rash, (2) knowledge of the reward - public knowledge of the current amount of the reward for reporting smallpox, and (3) containment - the percent of infected villages interrupting smallpox transmission within 14 days of detection. Failures to achieve these objectives led to the identification and implementation of improved strategies that eventually achieved eradication. Essential to this success was a tripartite partnership of the citizens of Bangladesh, the Bangladesh Ministry of Health, its field staff, and staff and resources mobilized by the World Health Organization.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723923PMC
http://dx.doi.org/10.1016/j.vaccine.2011.06.081DOI Listing

Publication Analysis

Top Keywords

smallpox eradication
12
smallpox
11
smallpox cases
8
smallpox transmission
8
infected villages
8
bangladesh
4
eradication bangladesh
4
bangladesh 1972-1976
4
1972-1976 rahima
4
rahima banu
4

Similar Publications

Mpox: emergence following smallpox eradication, ongoing outbreaks and strategies for prevention.

Curr Opin Infect Dis

January 2025

Division of Pediatric Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Purpose Of Review: This review focuses on the temporal relationship between the discontinuation of the global smallpox eradication effort with the rise of mpox in Africa and worldwide. It also discusses the global 2022 clade II mpox epidemic and the current 2024 clade I mpox outbreak. Newer findings on viral evolution and pathogenesis, plus current and future strategies for disease prevention, are reviewed.

View Article and Find Full Text PDF

Monkeypox (MPOX) is a zoonotic viral disease caused by the Monkeypox virus (MPXV), which has become the most significant public health threat within the genus since the eradication of the Variola virus (VARV). Despite the extensive attention MPXV has garnered, little is known about its clinical manifestations in humans. In this study, a high-throughput RNA sequencing (RNA-seq) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach was employed to investigate the transcriptional and metabolic responses of HEK293T cells to the MPXV A5L protein.

View Article and Find Full Text PDF

Art reveals core human emotions during catastrophes like epidemics, allowing people to narrate their coping stories. This review examines smallpox's historical evolution and treatment in Japan, integrating visual art with medical history. It provides chronological insights from smallpox's arrival and traditional remedies to the era of vaccination and public health measures leading to eventual eradication.

View Article and Find Full Text PDF

Mpox, formerly known as monkeypox, has re-emerged as a significant global health concern, particularly during the widespread outbreak of 2022. As an orthopoxvirus related to the eradicated smallpox virus, mpox has been primarily managed with smallpox vaccines and treatments, including the antiviral agent Tecovirimat. This systematic review aims to evaluate the effectiveness and safety of Tecovirimat in treating mpox, focusing on its use during the 2022 outbreak, especially among high-risk populations, including men who have sex with men and people living with HIV.

View Article and Find Full Text PDF

Plaque reduction neutralization test for smallpox vaccines: Laboratory optimization and validation method for immunogenicity assessment.

J Immunol Methods

January 2025

Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, CheongJu, Chungbuk, Republic of Korea. Electronic address:

The eradication of smallpox, a historic triumph in global public health, was accomplished without a complete conception of the mechanisms underlying vaccine-induced protection. Contemporary concerns regarding potential bioterrorism threats and the possibility of smallpox reemergence have spurred research efforts toward developing third-generation vaccines capable of effectively neutralizing the variola virus. Clinical trials for a third-generation smallpox vaccine (KVAC103) are underway to obtain licensure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!